No profile data available.
Viridian Therapeutics, Inc. (VRDN) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in Waltham, United States, with about 252 full-time employees.
It reported revenue of $70.85 million for fiscal year 2025, up 23359.9% from fiscal year 2024, and net income of -$342.60 million. Its market capitalization was $2.11 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Viridian Therapeutics reported $70.85 million in revenue for fiscal year 2025, up 23359.9% from $302,000 in fiscal year 2024.
$2.11 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include Immunovant, Inc. (IMVT), Kiniksa Pharmaceuticals International, plc (KNSA), Aurinia Pharmaceuticals Inc. (AUPH), Alvotech (ALVO).